Ganz, I think we'll get an update about DES soon, I believe Management had said so at last earnings report. When we do, that will put a fire under the share price IMO.
Right now we are a bit range bound, once they report about DES, we'll run up and before the main event,
The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 22, 2021.
News 
Market Data 
Discover 
AI
